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Abstract 
Purpose: To study the in vivo metabolism of kurarinone, a lavandulyl flavanone which is a major 
constituent of Kushen and a marker compound with many biological activities, using ultra-performance 
liquid chromatography coupled with linear ion trap Orbitrap mass spectrometry (UPLC-LTQ-Orbitrap-
MS).  
Methods: Six male Sprague-Dawley rats were randomly divided into two groups. First, kurarinone was 
suspended in 0.5 % carboxymethylcellulose sodium (CMC-Na) aqueous solution, and was given to rats 
(n = 3, 2 mL for each rat) orally at 50 mg/kg. A 2 mL aliquot of 0.5 % CMC-Na aqueous solution was 
administered to the rats in the control group. Next, urine samples were collected over 0-24 h after the 
oral administrations and all urine samples were pretreated by a solid phase extraction (SPE) method. 
Finally, all samples were analyzed by a UPLC-LTQ-Orbitrap mass spectrometry coupled with an 
electrospray ionization source (ESI) that was operated in the negative ionization mode. 
Results: A total of 11 metabolites, including the parent drug and 10 phase II metabolites in rat urine, 
were first detected and interpreted based on accurate mass measurement, fragment ions, and 
chromatographic retention times. The results were based on the assumption that kurarinone 
glucuronidation was the dominant metabolite that was excreted in rat urine. 
Conclusion: The results from this work indicate that kurarinone in vivo is typically transformed to non-
toxic glucuronidation metabolites, and these findings may help to characterize the metabolic profile of 
kurarinone. 
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Sophora flavescens Ait (Leguminosae) is a 
perennial shrub that is widely distributed in Asia, 
Oceania, and the Pacific Islands. For thousands 
of years, the dried roots of Sophora flavescens, 
also named ‘Kushen’, have been traditionally 
used in East Asian countries as an herbal 
medicine for the treatment of hepatitis, 
gastrointestinal hemorrhage and skin diseases.  
 
Phytochemical studies of Sophora flavescens 
described the isolation of quinolizidine alkaloids, 
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flavonoids and triterpenoids. The alkaloids in 
Sophora flavescens mainly consist of oxymatrine 
and matrine, which have been used clinically in 
China for the treatment of chronic hepatitis. 
Furthermore, several pharmacological products, 
such as injection oxymatrine and capsule 
matrine, are extensively used for the treatment of 
hepatitis and cancers in China. The flavonoids, 
which have been termed Kushen flavonoids, 
usually carry one or multiple prenyl units. Several 
studies have demonstrated that prenyl chains are 
crucial for the biological activity of flavonoids [1]. 
Therefore, the pharmacology of Kushen 
prenylated flavonoids has become an area of 
increased research because of their anti-diabetic, 
anti-arthritic, anti-inflammation, and anti-bacterial 
activities. 
 
Kurarinone, a lavandulyl flavanone, is a major 
constituent of Kushen flavonoids, and it has a 
concentration range of 4.79-16.07 mg/g [2]. It is 
considered to be a marker compound with many 
biological activities, such as anti-immune [3], 
anti-bacterial [4], anti-atherosclerosis [5], anti-
cancer [6], anti-carcinogenic [7] activities. 
Furthermore, some studies have suggested that 
kurarinone in combination with TRAIL has 
potential application for the treatment of tumors 
and gastric cancer [8], and it can also potentially 
increase the antitumor activity of Taxol [9]. 
 
Although kurarinone has various 
pharmacological effects, studies on the in vivo 
metabolism of kurarinone have rarely been 
reported. Yu [10] demonstrated that kurarinone 
induced remarkable cytotoxicity in primary rat 
hepatocytes and HL - 7702 cells, with IC50 values 
of 29.9 and 48.2 μM, respectively. The 
metabolism of kurarinone by human liver 
microsomes in vitro indicated that kuarinone 
could be extensively glucuronidated to decrease 
its cytotoxicity [11].  
 
Metabolism, which plays an important role in 
pharmacokinetics, can influence the biological 
activity and toxicity of drugs [12]. Further studies 
of kurarinone metabolism and the role of 
metabolism in biological activity or toxicity should 
be performed to provide a comprehensive 




Isolation and identification of kurarinone 
 
Kurarinone (Figure 1) was isolated in our 
laboratory from the ethanol extract of Sophora 
flavescens Ait.. A 5 kg quantity of dry kushen 
roots was extracted three times with ethanol. The 
ethanol extract was evaporated to dryness, and 
the dry residue was suspended in water and 
further partitioned in succession with ethyl 
acetate and butanol. Part of the ethyl acetate 
extractives was chromatographed over 1000 g of 
a silica gel column (200 - 300 mesh) using a 
CH2Cl2 - MeOH step gradient elution, yielding ten 
fractions. The fractions (NO. 6) were 
chromatographed on MCI GEL CHP20P using a 
MeOH - H2O step gradient elution, and they were 
purified further by preparative HPLC (C18) to 
yield kurarinone (3.01 g). Its structure was 
elucidated by the comprehensive interpretation of 
the ESI - MS and 1H, 13C NMR data. The 
kurarinone purity was higher than 99 % 




       Figure 1: Chemical structures of kurarinone 
 
Chemicals and materials 
 
HPLC grade acetonitrile, methanol, and formic 
acid were purchased from Fisher (NJ, USA). 
Ultra-pure water was prepared using a Milli-Q 
water purification system (Millipore, Billerica, MA, 
USA). Waters Oasis HLB solid-phase extraction 
(SPE) cartridges (3 cc/60 mg, 30 µm) were used. 
All other chemicals were of analytical grade and 
they were commercially available. 
 
Animal experiments and drug administration 
 
Six male Sprague-Dawley rats (200 ± 10 g) were 
provided by Southern Medical University 
Experimental Animals Center (Guangzhou, 
China). Sprague-Dawley rats were housed in 
controlled environmental conditions 
(temperature: 24 ± 2 oC; relative humidity: 70 ± 5 
%). They were housed individually for a week for 
acclimatization, and they were fed ad libitum with 
standard laboratory chow (Southern Medical 
University Experimental Animals Center, 
Guangzhou China) and water. All the rats were 
fasted for more than 12 h with free access to 
water before the experiment. The rats were 
randomly divided into two groups: Group A (n = 
3), drug group for urine; Group B (n = 3), control 
group for blank urine. All experimental protocols 
involving animals and their care were approved 
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(ref. no. SYXK (YUE) 2011 - 0015) by the 
institutional Animal Care and Use Committee at 
Southern Medical University (Guangzhou, 
China), and the experimental protocols followed 
the “Guide for the Care and Use of Laboratory 
Animals” [13]. 
 
Kurarinone (10 mg/mL) was suspended in 0.5 % 
carboxymethylcellulose sodium (CMC-Na) 
aqueous solution. The rats in the drug group 
were orally exposed to kurarinone at a dose of 
50 mg/kg body weight. Next, a 2 mL aliquot of 
0.5 % CMC-Na aqueous solution was 
administered to the rats in the control group. 
Urine samples were collected over a period of 0-
24 h after the oral administrations, and all the 
biological samples from the same group were 
pooled into one sample. 
 
Sample preparation  
 
All the rat urine samples were pretreated by a 
solid-phase extraction (SPE) method. A pre-
activated Oasis HLB solid phase extraction C18 
column was loaded with a 1 mL urine sample, 
and then the cartridge was eluted by 5 mL water 
and 5 mL methanol successively. The methanol 
eluate was collected and evaporated to dryness 
by N2. The residues were reconstituted in 100 µL 
methanol and then centrifuged at 14,000 rpm for 
15 min at 4 oC. The final 2 µL solution was 
injected into an UPLC-ESI-LTQ-Orbitrap MS for 
analysis. 
 
Instruments and conditions 
 
A Finnigan LTQ/Orbitrap MS (Thermo Electron, 
Bremen, Germany) coupled to an ESI source 
(Thermo Electron, Bremen, Germany) was used 
for all samples analysis. A Waters ACQUITY 
BEH C18 column (2.1 × 100 mm i.d., 1.7 µm) 
was used for separation of the metabolites at 
room temperature and a flow rate of 200 µL /min. 
A linear gradient elution using 0.5 % formic acid 
aqueous solution (A) and acetonitrile (B) was 
applied with the following program: 0 - 3 min, 3 - 
5 % B; 3 - 4 min, 5-30 % B; 4 - 20 min, 30 - 36 % 
B; 20 -21 min, 36 - 42 % B; 21 - 22 min, 42 - 60 
% B; 22 - 25 min, 60 - 61 % B; 25 - 26 min, 61 - 
80 % B; 26 - 30 min, 80 % B; 30 - 31 min, 80 - 3 
% B, and 31 - 35 min, 3 % B. 
 
An aliquot of 2 μL was injected into the UPLC-
LTQ Orbitrap MS. The optimized operating 
parameters in the negative ionization mode were 
as follows: capillary voltage of 35 V, electrospray 
voltage of 3.0 kV, capillary temperature of 350 
℃, sheath gas flow rate of 30 (arbitrary units), 
auxiliary gas flow rate of 10 (arbitrary units), and 
tube lens voltage of 110 V.  
Metabolites were detected by full scan mass-
analysis from m/z 100 to 1000 at a resolving 
power of 30,000 with data-dependent MS2 
analysis triggered by the three most-abundant 
ions from the precursor list of predicted 
metabolites followed by MS3 analysis of the most 
abundant product ions. Collision-induced 
dissociation (CID) was performed with an 
isolation width of 2 Da. The collision energy was 
set to 35 %. 
 
Peak selection and data processing 
 
Thermo Xcalibur 2.1 workstation (Thermo 
Scientific, Bremen, Germany) was used for data 
acquisition and processing. To obtain the 
maximum number of fragments, the peaks 
detected with intensity > 10000 were selected for 
identification. The chemical formulas for all 
parent ions of the selected peaks were 
calculated from the accurate mass using a 
formula predictor by setting the parameters as 
follows: C [0 - 40], H [0 - 50], O [0 - 20], S [0 - 4], 
N [0 - 4], Cl [0 - 4], and ring double bond (RDB) 
equivalent value [0 - 15]. Other elements such as 
P and Br were not considered, as they were 
rarely present in the complex matrix. Blank 
biological samples were used as controls to 
compare with the analyte samples, and they 




Fragmentation pathway of kurarinone 
 
First, the MSn fragmentation pattern of 
kurarinone was investigated to facilitate the 
structural identification of the metabolites. The 
parent ion showed a deprotonated ion [M − H]− at 
m/z 437.1950 (2.0 ppm, C26H29O6) in negative 
ionization mode. The fragmentation of this parent 
ion provided a characteristic fragment ion at m/z 
275 (C17H23O3) by the loss of the C9H6O3 moiety. 
The proposed fragmentation pattern of 
kurarinone is illustrated in Figure 2. 
 
Metabolites of kurarinone in rats 
 
After comparing the total ion chromatogram of 
the drug samples with the corresponding control 
samples, a total of 10 metabolites and the parent 
drug were detected and identified. The total ion 
chromatogram of the drug samples is shown in 
Figure 3. The chromatographic and mass 
spectrometric data of the parent drug and its 
metabolites are shown in Table 1. 
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  Figure 2: The proposed fragmentation pattern of kurarinone 
 
 




Metabolite M0 m/z 437.1958 (2.0 ppm, C26H29O6) 
eluted at 24.42 min, and it was unambiguously 
identified as kurarinone by comparing the 
retention time, accurate mass measurement and 
fragment ions with the authentic reference 
material. 
 
Metabolites M7 - 10 
 
Metabolites M7, M8, M9, and M10 were eluted at 
14.07, 14.33, 18.91 and 21.32 min, respectively. 
All of them yielded quasi-molecular ions of m/z 
613.2269 (1.7 ppm, C32H37O12), 613.2265 (2.4 
ppm, C32H37O12), 613.2267 (2.0 ppm, C32H37O12), 
and 613.2268 (1.9 ppm, C32H37O12), respectively. 
In the MS2 spectra, there was an abundant 
product ion at m/z 437 that was produced by the 
neutral loss of 176 Da, indicating that they were 
glucuronide conjugates. Therefore, M7 - M10 
were tentatively identified as glucuronidation of 
kurarinone. 
 
Metabolites M5 - 6 
 
Metabolites M5 and M6, with [M − H] ions at m/z 
789.2589 (1.4 ppm, C38H45O18) and m/z 
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H]- MS/MS fragment Identification/reactions 
1 7.97 629.2228 629.2218 -1.7 C32H37O13 




2 8.11 629.2228 629.2219 -1.5 C32H37O13 MS2 [629]: 291 (100), 453(98), 337(92) 
Glucuronidation and 
Hydroxylation 
3 8.48 629.2228 629.2221 -1.2 C32H37O13 MS2 [629]: 453(100), 291(2) 
Glucuronidation and 
Hydroxylation 
4 8.74 629.2228 629.2217 -1.9 C32H37O13 




5 10.62 789.2600 789.2589 -1.4 C38H45O18 MS
2 [789]: 613 (100), 293(68), 437(10) Diglucuronidation 
6 11.14 789.2600 789.2588 -1.6 C38H45O18 MS
2 [789]: 613 (100), 437(8) Diglucuronidation 
7 14.07 613.2279 613.2269 -1.7 C32H37O12 
MS2 [613]: 337 (100), 437(92), 275(43), 
419(21) 
Glucuronidation 
8 14.33 613.2279 613.2265 -2.4 C32H37O12 
MS2 [613]: 337 (100), 437(85), 275(36), 
419(14) 
Glucuronidation 
9 18.91 613.2279 613.2267 -2.0 C32H37O12 
MS2 [613]: 437 (100), 293(78), 275(22), 
419(8) 
Glucuronidation 
10 21.32 613.2279 613.2268 -1.9 C32H37O12 
MS2 [613]: 437 (100), 293(68), 275(35), 
419(4) 
Glucuronidation 
0 24.42 437.1958 437.1950 -2.0 C26H29O6 MS
2 [437]: 161 (100), 275(28) Parent drug 
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789.2588 (1.6 ppm, C38H45O18) eluted at 10.62 
and 11.14 min, respectively. 
 
In MS2 spectra, there was an abundant product 
ion at m/z 613 that was generated by the neutral 
loss of 176 Da, indicating that they were 
glucuronide conjugates. The MS3 of M5 and M6 
possessed the same MS2 spectra as M7 - 10, 
suggesting that the core structure of M5 and M6 




Metabolites M1, M2, M3, and M4 eluted at 7.97, 
8.11, 8.48, and 8.74 min, respectively. All of 
them yielded [M−H]− ions at m/z 629.2218 (1.7 
ppm, C32H37O13), 629.2219 (1.5 ppm, C32H37O13), 
629.2221 (1.2 ppm, C32H37O13), and 629.2217 
(1.9 ppm, C32H37O13), respectively. In the MS2 
spectra, there was an abundant product ion at 
m/z 453 that was produced by the neutral loss of 
176 Da, indicating that they were glucuronide 
conjugates. The fragment ion at m/z 453 was 
present in the MS spectra, which was contained 
more O atoms more than M0 suggesting that it 
was a hydroxylation kurarinone ion. Therefore, 
M1 - M4 were tentatively identified as 




Our results indicated that in vivo the kurarinone 
is typically transformed to non - toxic 
glucuronidation metabolites by phase II drug-
metabolizing enzymes. In general, xenobiotics or 
drug compounds that are introduced into the 
body typically undergo metabolism, elimination 
and/or detoxification, then they are transformed 
to non-toxic metabolites by phase I and phase II 
drug-metabolizing enzymes. In general, 
conjugation with phase II DMEs (including 
sulfotransferases, UDP – glucuronosyltrans-
ferases and epoxide hydrolases) increases 
hydrophilicity, thereby enhancing excretion in the 
bile and/or the urine which consequently has a 
detoxification effect. 
 
Although our results indicated that the UDP - 
glucuronosyltransferases (UGT) play important 
roles in kurarinone metabolic pathways and a 
series of glucuronidation metabolic reactions 
after the oral administration kurarinone, 
metabolites M1 - 4 indicated that the 
hydroxylation of kurarinone also occurs, but it 
has a short half - life. The in vitro investigation of 
kurarinone metabolism in human liver 
microsomes also suggests that the hydroxylation 
of kurarinone was much slower than 
glucuronidation [11]. Our results suggested that 
kurarinone glucuronidation is considered to be 
more important than other metabolic pathway of 





The UPLC-LTQ-Orbitrap technique has been 
successfully applied to analyze the metabolic 
profile of orally administered kurarinone in 
Sparague-Dawley rat urine. A total of 10 
metabolites and the parent drug were detected 
and identified based on accurate mass 
measurements, fragmentation patterns and 
chromatographic retention times. 
 
To the best of our knowledge, this report is the 
first to describe the metabolism of kurarinone in 
vivo. The results indicate that kurarinone in vivo 
is typically transformed to non-toxic 
glucuronidation metabolites, and these findings 
help to characterize the metabolic profile of 
kurarinone in human liver microsomes in vitro by 
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